Carvedilol controlled release - RedHill Biopharma

Drug Profile

Carvedilol controlled release - RedHill Biopharma

Alternative Names: Cardio; EG-P042; RHB-101

Latest Information Update: 10 Dec 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Egalet
  • Developer RedHill Biopharma
  • Class Antihypertensives; Carbazoles; Ethanolamines; Heart failure therapies; Ischaemic heart disorder therapies; Phenyl ethers; Propanolamines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Alpha beta adrenergic receptor antagonists; Beta-adrenergic receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Heart failure; Hypertension; Left ventricular dysfunction

Most Recent Events

  • 10 Dec 2015 Clinical trials in Heart failure in Israel (PO)
  • 10 Dec 2015 Clinical trials in Hypertension in Israel (PO)
  • 10 Dec 2015 Clinical trials in Left ventricular dysfunction in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top